Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clozapine-induced agranulocytosis and thrombopenia in a patient with dopaminergic psychosis.

Literature DB >> 9503276

Clozapine-induced agranulocytosis and thrombopenia in a patient with dopaminergic psychosis.

J Rudolf¹, M Grond, M Neveling, W D Heiss.

Abstract

In patients with Parkinson' disease and dopaminergic psychosis, clozapine treatment is recommended as the drug is free from extrapyramidal side effects and does not worsen motor symptoms of the underlying disease. The use of clozapine, however, is limited due to its hematotoxic side effects. For treatment of clozapine-induced agranulocytosis, granulocyte colony-stimulating factors (G-CSF) are recommended. We report the case of a 72-years-old male patient with clozapine-induced agranulocytosis and thrombopenia. Neutropenia was successfully treated with G-CSF, but thrombopenia persisted and resolved spontaneously after 14 days. Bone marrow toxicity of clozapine is not restricted to white cell maturation, but may also impair thrombocytopoesis.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1997 PMID： 9503276 DOI： 10.1007/BF01294731

Source DB: PubMed Journal: J Neural Transm (Vienna) ISSN： 0300-9564 Impact factor: 3.575

21 in total

1. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland.

Authors: K Atkin; F Kendall; D Gould; H Freeman; J Liberman; D O'Sullivan
Journal: Br J Psychiatry Date: 1996-10 Impact factor: 9.319

Review 2. Psychiatric side effects of levodopa in man.

Authors: F K Goodwin
Journal: JAMA Date: 1971-12-27 Impact factor: 56.272

3. Parkinsonism: onset, progression and mortality.

Authors: M M Hoehn; M D Yahr
Journal: Neurology Date: 1967-05 Impact factor: 9.910

4. Platelet dysfunction associated with clozapine therapy.

Authors: R Durst; A Dorevitch; Y Fraenkel
Journal: South Med J Date: 1993-10 Impact factor: 0.954

5. Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease.

Authors: M M Pinter; R J Helscher
Journal: J Neural Transm Park Dis Dement Sect Date: 1993

6. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease.

Authors: J M Rabey; T A Treves; M Y Neufeld; E Orlov; A D Korczyn
Journal: Neurology Date: 1995-03 Impact factor: 9.910

Review 7. Role of serotonin in the action of atypical antipsychotic drugs.

Authors: H Y Meltzer
Journal: Clin Neurosci Date: 1995

Review 8. On the possible mechanisms and predictability of clozapine-induced agranulocytosis.

Authors: A V Pisciotta; S A Konings; L L Ciesemier; C E Cronkite; J A Lieberman
Journal: Drug Saf Date: 1992 Impact factor: 5.606

9. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.

Authors: J M Alvir; J A Lieberman; A Z Safferman; J L Schwimmer; J A Schaaf
Journal: N Engl J Med Date: 1993-07-15 Impact factor: 91.245

Review 10. G-CSF and the management of clozapine-induced agranulocytosis.

Authors: S L Gerson
Journal: J Clin Psychiatry Date: 1994-09 Impact factor: 4.384

5 in total

1. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up.

Authors: P Pollak; F Tison; O Rascol; A Destée; J J Péré; J M Senard; F Durif; I Bourdeix
Journal: J Neurol Neurosurg Psychiatry Date: 2004-05 Impact factor: 10.154

2. The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview.

Authors: T Prohorov; C Klein; A Miniovitz; E Dobronevsky; J M Rabey
Journal: J Neurol Date: 2005-08-17 Impact factor: 4.849